Frontage Europe Enhances Its Bioanalytical Laboratory with Strategic Relocation

Frontage Europe's Strategic Move to Milan

In an exciting development for the bioanalytical services sector, Frontage Europe has made a significant operational enhancement by relocating its bioanalytical laboratory to a larger and more efficient facility near Milan, Italy. This 2,500 square meters state-of-the-art laboratory aims to consolidate all services and streamline processes, ultimately improving client offerings.

Reasons for the Relocation

The primary goal of this move is to boost the efficiency of operations. By positioning the lab close to Milan, Frontage Europe aims to facilitate better logistics and project management for clinical studies, benefitting clients who rely on bioanalytical services for regulatory approvals and drug development.

The facility is conveniently located just 25 kilometers from Malpensa Airport, allowing for smoother logistics when it comes to sample transportation. This strategic geographical location is particularly crucial for clients who need quick turnaround times and efficient handling of sensitive samples.

Advanced Capabilities

The relocated laboratory is equipped with cutting-edge technology. It features advanced instruments for quantitative mass spectrometry, ligand-binding, and biomarker assays. Among the various platforms available within the new facility are the LC-MS/MS, Meso Scale Discovery, Quanterix Simoa HD-X, and ELISA assays. The laboratory has also integrated the Lumipulse G1200 instrument to enhance its assay capabilities.

Adhering to stringent quality standards is a priority for Frontage Europe. The laboratory operates under a Good Laboratory Practice (GLP) quality system and complies with Good Clinical Practice (GCP), ensuring that all bioanalytical assays and sample analyses meet international regulatory guidelines, including the ICH M10 guidance.

New Services for Clients

To further meet the evolving demands of clients, Frontage Europe has recently added Central Lab services, focused on providing logistical support and project management for clinical studies. This expansion includes investments in analytical and sample processing capabilities, as well as in-house storage options featuring -80°C and -20°C freezers.

Moreover, they now offer custom synthesis services for a range of radiolabeled and stable-labeled compounds, enhancing their portfolio in pharmacokinetic studies. The scientific team at Frontage can assist clients by analyzing the metabolism of compounds using high-resolution mass spectrometry methods on various matrices, including in-vitro and in-vivo samples from preclinical and clinical studies.

Ongoing Commitment to Excellence

With over 25 years of experience, Frontage Laboratories Inc. has established itself as a key player in the Contract Research, Development, and Manufacturing Organization (CRDMO) landscape. Operating 26 facilities worldwide, the company has made substantial contributions to helping clients navigate the complex landscape of drug development and regulatory approvals across multiple regions, including the US, Canada, Europe, and Asia.

The management expresses enthusiasm about this relocation and expansion initiative, believing it positions Frontage Europe to deliver enhanced services and support to its clients in the pharmaceutical and biotech industries. For those interested in discovering more about Frontage Europe's expanded capabilities, they are encouraged to reach out via email for further information and collaboration opportunities.